Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 10, 2014
Context: The filing reports the completion of a private placement offering of American Depositary Shares (ADSs) and warrants to accredited and institutional investors.
Key Financial Metrics and Transaction Details
- Shares Issued: 982,344 ADSs at a purchase price of $5.15 per ADS.
- Warrants Issued: 491,172 warrants to purchase additional ADSs (50% of shares issued).
- Warrant Terms: Exercise price of $6.43 per ADS; exercisable after September 10, 2014, for a four-year period. Cashless exercise permitted if no effective registration statement exists.
- Placement Agent: Roth Capital Partners, LLC.
- Placement Fees: $303,545 cash fee plus warrants to purchase 49,117 ADSs (1% of shares issued) at $6.43 per ADS.
- Regulatory Status: Offered under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Material Changes and Agreements
The filing details a significant capital raise event and associated contractual obligations:
- Registration Rights: The Company agreed to file a registration statement within 30 days of closing and use reasonable best efforts to have it declared effective within 60 days (or 90 days if fully reviewed).
- Delay Payments: If registration is delayed, the Company must pay monthly fees of 1% of the purchase price, capped at an aggregate of 9%.
- Lock-Up Agreements: Officers and directors are restricted from selling securities for 30 days after the registration statement becomes effective. The Company is restricted from issuing new securities for 60 days post-closing.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the execution of the financing and does not provide operational guidance or clinical trial updates.
Risks and Contingencies:
- Registration Risk: Failure to timely file or declare the registration statement effective triggers financial penalties (delay payments).
- Dilution: The issuance of shares and warrants, along with potential future exercise of warrants, will dilute existing shareholders.
- Liquidity Constraints: The lock-up agreements restrict the ability of insiders and the Company to access the public market for a defined period.
Investor Verification Checklist
- Verify the total gross proceeds raised (982,344 ADSs x $5.15) and net proceeds after deducting the $303,545 placement fee.
- Confirm the status of the Registration Statement filing and its effectiveness date to assess potential delay payment liabilities.
- Review the full text of the Securities Purchase Agreement (Exhibit 99.1) for specific adjustment mechanisms on the warrant exercise price.
- Check subsequent filings to ensure the 60-day corporate lock-up and 30-day insider lock-up periods were adhered to.